文献速递前列腺癌

纳入2014年国际泌尿病理学会Gleason分级及筛状生长模式改进鹿特丹欧洲前列腺癌筛查随机研究风险计算器用于初次前列腺活检

Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
PubMed 文献 · Eur Urol · 2017-02-02

基于鹿特丹ERSPC第一轮筛查3616名男性及885例前列腺癌病理复核,将2014年ISUP分级和筛状/导管内癌纳入风险计算器RC3。更新后模型区分无癌、低危和高危前列腺癌的AUC分别为0.70和0.92;在1%风险阈值下可减少34%不必要活检,仅2%高危前列腺癌漏诊。

要点

  • 更新RC3纳入年龄、PSA、直肠指检和前列腺体积预测低危和高危前列腺癌。
  • 无癌与低危、高危前列腺癌的AUC分别为0.70(95%CI 0.68-0.72)和0.92(95%CI 0.90-0.94)。
  • 1%风险阈值下不必要活检减少34%,高危前列腺癌漏诊仅2%。

核心结论

  • 结合高敏感性现代病理活检分类的简易风险分层工具可显著减少不必要前列腺活检和潜在惰性病的过度诊断。

研究设计与样本

  • 基于鹿特丹ERSPC第一轮筛查3616名男性的RC3,2015年复核885例前列腺癌病理切片。
  • 低危前列腺癌定义为ISUP 1级或2级不伴筛状/导管内癌;高危定义为ISUP 2级伴筛状/导管内癌或ISUP≥3级。
  • 采用多项逻辑回归更新RC3,纳入年龄、PSA、直肠指检和前列腺体积预测低危和高危前列腺癌。

主要发现

  • 无癌男性与低危前列腺癌的AUC为0.70(95%CI 0.68-0.72)。
  • 无癌男性与高危前列腺癌的AUC为0.92(95%CI 0.90-0.94)。
  • 1%风险阈值下更新计算器使不必要活检减少34%,仅2%高危前列腺癌漏诊。

关键数值与推荐

  • 低危前列腺癌:ISUP 1级或2级不伴筛状/导管内癌。
  • 高危前列腺癌:ISUP 2级伴筛状/导管内癌或ISUP≥3级。
  • 1%风险阈值下不必要活检减少34%,高危前列腺癌漏诊2%。

临床怎么用

  • 更新风险计算器可个体化预测活检可检出(潜在侵袭性)前列腺癌的概率。
  • 该工具可在考虑前列腺活检时引导共享决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The survival rate for men with International Society of Urological Pathology (ISUP) grade 2 prostate cancer (PCa) without invasive cribriform (CR) and intraductal carcinoma (IDC) is similar to that for ISUP grade 1. If updated into the European Randomized Study of Screening for Prostate Cancer (ERSPC Rotterdam) risk calculator number 3 (RC3), this may further improve upfront selection of men who need a biopsy. OBJECTIVE: To improve the number of possible biopsies avoided, while limiting undiagnosed clinically important PCa by applying the updated RC3 for risk-based patient selection. DESIGN, SETTING, AND PARTICIPANTS: The RC3 is based on the first screening round of the ERSPC Rotterdam, which involved 3616 men. In 2015, histopathologic slides for PCa cases (n=885) were re-evaluated. Low-risk (LR) PCa was defined as ISUP grade 1 or 2 without CR/IDC. High-risk (HR) PCa was defined as ISUP grade 2 with CR/IDC and PCa with ISUP grade≥3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We updated the RC3 using multinomial logistic regression analysis, including data on age, PSA, digital rectal examination, and prostate volume, for predicting LR and HR PCa. Predictive accuracy was quantified using receiver operating characteristic analysis and decision curve analysis. RESULTS AND LIMITATIONS: Men without PCa could effectively be distinguished from men with LR PCa and HR PCa (area under the curve 0.70, 95% confidence interval [CI] 0.68-0.72 and 0.92, 95% CI 0.90-0.94). At a 1% risk threshold, the updated calculator would lead to a 34% reduction in unnecessary biopsies, while only 2% of HR PCa cases would be undiagnosed. CONCLUSIONS: A relatively simple risk stratification tool augmented with a highly sensitive contemporary pathologic biopsy classification would result in a considerable decrease in unnecessary prostate biopsies and overdiagnosis of potentially indolent disease. PATIENT SUMMARY: We improved a well-known prostate risk calculator with a new pathology classification system that better reflects disease burden. This new risk calculator allows individualized prediction of the chance of having (potentially aggressive) biopsy-detectable prostate cancer and can guide shared decision-making when considering prostate biopsy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Roobol MJ, Verbeek JFM, van der Kwast T, et al. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. Eur Urol. 2017. PMID: 28162815. doi:10.1016/j.eururo.2017.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。